Ensuring Timely Access to Generics Act of 2019
Latest action · May 2, 2019 Referred to the Subcommittee on Health.
Progress
Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.
- IntroducedMay 1, 2019
- Passed HouseNot reached
- Passed SenateNot reached
- To the PresidentNot reached
- Became lawNot reached
Summary
Ensuring Timely Access to Generics Act of 2019
This bill requires the Food and Drug Administration (FDA) to consider certain factors in determining whether a petition is submitted for the primary purpose of delaying the approval of a drug application.
The FDA must (1) publish a list of petitions that were submitted with an intent to delay, and (2) establish procedures to refer such petitions to the Federal Trade Commission.
The FDA may establish a timeline for submitting petitions.
Cosponsors 6
Members who signed on, in the order they did. Signatures ran from May 1, 2019 to Jun 13, 2019; 1 is an original cosponsor, there from the day it was introduced.
| Seat | Cosponsor | Signed on | |
|---|---|---|---|
| D-NY | Anthony Brindisi | Original | May 1, 2019 |
| D-CO | Jason Crow | May 28, 2019 | |
| R-FL | Michael Waltz | May 28, 2019 | |
| R-TX | Ron Wright | May 28, 2019 | |
| R-PA | Brian K. Fitzpatrick | Jun 5, 2019 | |
| R-PA | Lloyd Smucker | Jun 13, 2019 |
Committees 1
Where it was sent and what each committee and subcommittee did with it, in order.
| Chamber | Committee | What it did |
|---|---|---|
| House | Energy and Commerce Committee | Referred May 1, 2019 |
| Health Subcommittee | Referred May 2, 2019 |
Actions 3
Everything that happened, newest first.
- May 2, 2019Referred to the Subcommittee on Health.
- May 1, 2019Introduced in House
- May 1, 2019Referred to the House Committee on Energy and Commerce.
Research
What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.
Constitutional authority
The sponsor’s statement, as printed in the Congressional Record, vol. 165, no. 71, May 1, 2019, page H3406.
CRS reports 1
Congressional Research Service work that CRS links to this bill or the law it became, newest first.
Cite it 1
Products on other subjects that cite it, usually among other measures.
| Product | Title | Kind | Published |
|---|---|---|---|
| R46741 | Drug Pricing and Intellectual Property: The Legislative Landscape for the 117th Congress | Report | Mar 31, 2021 |
Related bills 2
Companion bills and other measures the record links to this one.
| Bill | Title | Relationship | Latest action |
|---|---|---|---|
| S 1169 | Ensuring Timely Access to Generics Act of 2019 | Identical bill | Apr 11, 2019 |
| S 3384 | Lowering Prescription Drug Prices for America’s Seniors and Families Act of 2020 | Related bill | Mar 3, 2020 |
Titles 2
Every title it has carried, official and short, at each stage.
- Official Title as Introduced
- To amend the Federal Food, Drug, and Cosmetic Act with respect to citizen petitions.
- Short Title(s) as Introduced
- Ensuring Timely Access to Generics Act of 2019
Subjects
Assigned by the Library of Congress. Policy area: Health.
Text 1
Each version as it was printed, newest first.
- May 1, 2019Introduced in House
Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.